Search Results 651-660 of 24203 for In situ
... in treating patients with HER2 expressing ductal carcinoma in situ. H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of ...
... in patients with recurrent or metastatic HPV-16 positive advanced malignancies. ... In the phase Ib: safety will be assessed in ... situ cancers: bladder, gastric, ...
The atypical cells may continue to build up. The cells are trapped in the breast duct. This is called ductal carcinoma in situ. E. Eventually the cancer cells ...
... in situ) during the 5 years prior to randomization. Cancer treated with curative intent > 5 years prior to randomization and without evidence of recurrence ...
... in a trial will be enrolled. Contact ... All cancer cases with an ICD-O histologic behavior code of two “2” (carcinoma in situ) or three “3” (malignant); ...
... situ carcinoma of the cervix uteri, basal cell ... in safety expansion) in combination with bortezomib and dexamethasone. ... A total of 66 patients were enrolled ( ...
Malignant condition in the past 12 months (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ). Pregnant or ...
Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are allowed;; Patients with a ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.